{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T10:07:23Z","timestamp":1789034843122,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.esmogo.2026.100412","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:13:04Z","timestamp":1789031584000},"page":"100412","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intra- and intertumoral discordance of Claudin-18.2: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-4931-9897","authenticated-orcid":false,"given":"T.L.M.","family":"Vanneste","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2243-1269","authenticated-orcid":false,"given":"D.I.R.","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7080-1872","authenticated-orcid":false,"given":"S.","family":"van der Mierden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.A.","family":"Vollebergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.L.","family":"Kodach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"van Sandick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.G.H.","family":"Beets-Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1086-8108","authenticated-orcid":false,"given":"P.","family":"Snaebjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2617-8128","authenticated-orcid":false,"given":"Z.","family":"Bodalal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.esmogo.2026.100412_bib1","doi-asserted-by":"crossref","first-page":"7624","DOI":"10.1158\/1078-0432.CCR-08-1547","article-title":"Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development","volume":"14","author":"Sahin","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100412_bib2","doi-asserted-by":"crossref","first-page":"679","DOI":"10.3390\/cancers16030679","article-title":"Claudin 18.2 as a new biomarker in gastric cancer\u2014what should we know?","volume":"16","author":"Mathias-Machado","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"21","key":"10.1016\/j.esmogo.2026.100412_bib3","doi-asserted-by":"crossref","first-page":"7380","DOI":"10.1128\/MCB.21.21.7380-7390.2001","article-title":"Claudin-18, a novel downstream target gene for the T\/EBP\/NKX2.1 homeodomain transcription factor, encodes lung- and stomach-specific isoforms through alternative splicing","volume":"21","author":"Niimi","year":"2001","journal-title":"Mol Cell Biol"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100412_bib4","doi-asserted-by":"crossref","first-page":"3367","DOI":"10.21037\/tcr-19-1876","article-title":"Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer","volume":"9","author":"Hong","year":"2020","journal-title":"Transl Cancer Res"},{"issue":"16","key":"10.1016\/j.esmogo.2026.100412_bib5","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.3390\/cells14161285","article-title":"Claudin18.2 as a promising therapeutic target in gastric cancer","volume":"14","author":"Poniewierska-Baran","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.esmogo.2026.100412_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1596460","article-title":"Tight junctional protein family, claudins in cancer and cancer metastasis","volume":"15","author":"Ji","year":"2025","journal-title":"Front Oncol"},{"issue":"10389","key":"10.1016\/j.esmogo.2026.100412_bib7","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/S0140-6736(23)00620-7","article-title":"Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial","volume":"401","author":"Shitara","year":"2023","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100412_bib8","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-023-02465-7","article-title":"Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial","volume":"29","author":"Shah","year":"2023","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100412_bib9","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","article-title":"Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results","volume":"28","author":"Qi","year":"2022","journal-title":"Nat Med"},{"issue":"23","key":"10.1016\/j.esmogo.2026.100412_bib10","doi-asserted-by":"crossref","first-page":"4944","DOI":"10.1158\/1078-0432.CCR-24-4280","article-title":"A first-in-human study of givastomig, a CLDN18.2 and 4-1BB bispecific antibody, as monotherapy in patients with CLDN18.2-positive advanced or metastatic solid tumors","volume":"31","author":"Ku","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100412_bib11","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S1470-2045(24)00636-3","article-title":"Claudin 18.2-targeting antibody-drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial","volume":"26","author":"Ruan","year":"2025","journal-title":"Lancet Oncol"},{"issue":"10494","key":"10.1016\/j.esmogo.2026.100412_bib12","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.esmogo.2026.100412_bib13","doi-asserted-by":"crossref","first-page":"6453","DOI":"10.1158\/1078-0432.CCR-20-2085","article-title":"Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy","volume":"26","author":"Zhou","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100412_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100589","article-title":"Claudin-18.2 immunohistochemical evaluation in gastric and gastroesophageal junction adenocarcinomas to direct targeted therapy: a practical approach","volume":"37","author":"Fassan","year":"2024","journal-title":"Mod Pathol"},{"key":"10.1016\/j.esmogo.2026.100412_bib15","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100412_bib16","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1007\/s10120-024-01518-1","article-title":"Global prevalence of claudin 18 isoform 2 in tumors of patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma","volume":"27","author":"Shitara","year":"2024","journal-title":"Gastric Cancer"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100412_bib17","doi-asserted-by":"crossref","first-page":"639","DOI":"10.5230\/jgc.2025.25.e47","article-title":"Correlation and overlap between claudin 18.2 and FGFR2b overexpression: a tissue microarray study with 1,538 gastric carcinomas","volume":"25","author":"Ahn","year":"2025","journal-title":"J Gastric Cancer"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100412_bib18","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s10120-025-01609-7","article-title":"Heterogeneity of predictive biomarker expression in gastric and esophago-gastric junction carcinoma with peritoneal dissemination","volume":"28","author":"Angerilli","year":"2025","journal-title":"Gastric Cancer"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100412_bib19","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41416-019-0508-4","article-title":"Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled cases","volume":"121","author":"Coati","year":"2019","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100412_bib20","doi-asserted-by":"crossref","first-page":"14","DOI":"10.32604\/or.2026.075609","article-title":"Claudin 18.2 expression in gastric adenocarcinoma: diagnostic reproducibility and clinicopathologic associations in a Western cohort","volume":"34","author":"D\u00edaz Del Arco","year":"2026","journal-title":"Oncol Res"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100412_bib21","article-title":"Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer","volume":"13","author":"Kim","year":"2023","journal-title":"Sci Rep"},{"issue":"12","key":"10.1016\/j.esmogo.2026.100412_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.104000","article-title":"Clinicopathological analysis of claudin 18.2 focusing on intratumoral heterogeneity and survival in patients with metastatic or unresectable gastric cancer","volume":"9","author":"Kim","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmogo.2026.100412_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2024.155628","article-title":"Expression of claudin 18.2 in poorly cohesive carcinoma and its association with clinicopathologic parameters in East Asian patients","volume":"263","author":"Kim","year":"2024","journal-title":"Pathol Res Pract"},{"issue":"12","key":"10.1016\/j.esmogo.2026.100412_bib24","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/PAS.0000000000002464","article-title":"Claudin 18.2 and other therapeutic biomarkers in gastric and gastroesophageal junction adenocarcinomas","volume":"49","author":"Liu","year":"2025","journal-title":"Am J Surg Pathol"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100412_bib25","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s10147-026-02972-w","article-title":"Intratumoral heterogeneity and chemotherapy-induced alteration of CLDN18.2 expression in resectable gastric cancer","volume":"31","author":"Nagano","year":"2026","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100412_bib26","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-12337-4","article-title":"The expression of the tight junction protein and therapeutical target claudin 18.2 is heterogeneously distributed within esophageal and gastric adenocarcinoma","volume":"15","author":"Pak","year":"2025","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100412_bib27","doi-asserted-by":"crossref","first-page":"303","DOI":"10.5230\/jgc.2025.25.e2","article-title":"Discordance in claudin 18.2 expression between primary and metastatic lesions in patients with gastric cancer","volume":"25","author":"Son","year":"2025","journal-title":"J Gastric Cancer"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100412_bib28","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/10668969251411556","article-title":"Expression of claudin 18.2 and its prognostic significance in patients with Japanese gastric solid-type poorly differentiated adenocarcinoma","volume":"34","author":"Umekita","year":"2026","journal-title":"Int J Surg Pathol"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100412_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.105049","article-title":"Claudin 18.2: a promising actionable target in biliary tract cancers","volume":"10","author":"Angerilli","year":"2025","journal-title":"ESMO Open"},{"issue":"2","key":"10.1016\/j.esmogo.2026.100412_bib30","doi-asserted-by":"crossref","first-page":"671","DOI":"10.21037\/jgo-2024-925","article-title":"Claudin 18 immunohistochemistry in cholangiocarcinoma","volume":"16","author":"Desai","year":"2025","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.esmogo.2026.100412_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.106014","article-title":"High fidelity of Claudin-18.2 expression in primary and matched metastatic (lymph nodes, peritoneum, and liver) pancreatic ductal adenocarcinoma: a foundation for targeted therapy","volume":"168","author":"Franzina","year":"2026","journal-title":"Hum Pathol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100412_bib32","doi-asserted-by":"crossref","DOI":"10.1080\/21688370.2025.2535047","article-title":"Concordance of claudin-18.2 expression in biopsy, resection, and recurrent specimens: implications for zolbetuximab therapy in pancreatic ductal adenocarcinoma","volume":"14","author":"Kyuno","year":"2026","journal-title":"Tissue Barriers"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100412_bib33","article-title":"Heterogeneity of claudin 18.2 expression in metastatic gastric cancer","volume":"14","author":"Choi","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100412_bib34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s00428-024-03756-1","article-title":"Spatial expression of claudin 18.2 in matched primaries and metastases of tubo-ovarian carcinoma of all subtypes","volume":"485","author":"Wagner","year":"2024","journal-title":"Virchows Arch"},{"issue":"12","key":"10.1016\/j.esmogo.2026.100412_bib35","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1007\/s12094-020-02380-0","article-title":"Prognostic impact of claudin 18.2 in gastric and esophageal adenocarcinomas","volume":"22","author":"Arnold","year":"2020","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100412_bib36","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.21873\/invivo.13954","article-title":"Claudin 18.2 expression in gastric tumors and other tumor types with gastric epithelium-like differentiation","volume":"39","author":"Kim","year":"2025","journal-title":"In Vivo"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100412_bib37","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1007\/s00595-025-03189-6","article-title":"Spatial discordance of claudin18.2 in gastric cancer: clinical implications for patient selection in Zolbetuximab therapy","volume":"56","author":"Ozawa","year":"2026","journal-title":"Surg Today"},{"issue":"9","key":"10.1016\/j.esmogo.2026.100412_bib38","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1093\/jjco\/hyz068","article-title":"Comparison of claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma","volume":"49","author":"Rohde","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100412_bib39","doi-asserted-by":"crossref","DOI":"10.1200\/PO.23.00543","article-title":"Retrospective study of claudin 18 isoform 2 prevalence and prognostic association in gastric and gastroesophageal junction adenocarcinoma","volume":"8","author":"Waters","year":"2024","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.esmogo.2026.100412_bib40","doi-asserted-by":"crossref","DOI":"10.1007\/s00428-026-04544-9","article-title":"Real world clinical characteristics of claudin 18.2 expression in patients with pancreatic adenocarcinoma","author":"Kerper","year":"2026","journal-title":"Virchows Arch"},{"issue":"3","key":"10.1016\/j.esmogo.2026.100412_bib41","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/ijc.28400","article-title":"Claudin 18.2 is a target for IMAB362 antibody in pancreatic neoplasms","volume":"134","author":"W\u00f6ll","year":"2014","journal-title":"Int J Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100412_bib42","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1186\/s12885-025-13940-4","article-title":"Claudin 18.2 expression profile in primary tumors and their ovarian metastases: implications for targeted therapy","volume":"25","author":"Kim","year":"2025","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100412_bib43","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1007\/s10120-024-01505-6","article-title":"Claudin-18 status and its correlation with HER2 and PD-L1 expression in gastric cancer with peritoneal dissemination","volume":"27","author":"Ogawa","year":"2024","journal-title":"Gastric Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100412_bib44","doi-asserted-by":"crossref","first-page":"67","DOI":"10.21037\/jgo-24-743","article-title":"Expression of claudin18.2 in metastatic lesions in peritoneum of gastric cancer","volume":"16","author":"Saito","year":"2025","journal-title":"J Gastrointest Oncol"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100412_bib45","doi-asserted-by":"crossref","first-page":"529","DOI":"10.7326\/0003-4819-155-8-201110180-00009","article-title":"QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies","volume":"155","author":"Whiting","year":"2011","journal-title":"Ann Intern Med"},{"issue":"4260","key":"10.1016\/j.esmogo.2026.100412_bib46","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1126\/science.959840","article-title":"The clonal evolution of tumor cell populations","volume":"194","author":"Nowell","year":"1976","journal-title":"Science"},{"issue":"7381","key":"10.1016\/j.esmogo.2026.100412_bib47","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/nature10762","article-title":"Clonal evolution in cancer","volume":"481","author":"Greaves","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100412_bib48","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12885-023-10533-x","article-title":"Claudin18.2 as a potential therapeutic target for primary ovarian mucinous carcinomas and metastatic ovarian mucinous carcinomas from upper gastrointestinal primary tumours","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100412_bib49","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1111\/his.15407","article-title":"Expression of claudin-18.2 in cholangiocarcinoma: a comprehensive immunohistochemical analysis from a German tertiary centre","volume":"86","author":"Kinzler","year":"2025","journal-title":"Histopathology"},{"key":"10.1016\/j.esmogo.2026.100412_bib50","article-title":"Dark horse target Claudin18.2 opens new battlefield for pancreatic cancer","volume":"14","author":"Xu","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2026.100412_bib51","first-page":"971","article-title":"Immunohistochemical analysis of claudin expression in pancreatic cystic tumors","volume":"25","author":"Lee","year":"2011","journal-title":"Oncol Rep"},{"issue":"31","key":"10.1016\/j.esmogo.2026.100412_bib52","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.3748\/wjg.v25.i31.4343","article-title":"Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas","volume":"25","author":"Zaccari","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100412_bib53","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.trecan.2020.02.001","article-title":"Tumor plasticity and resistance to immunotherapy","volume":"6","author":"Horn","year":"2020","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100412_bib54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1186\/s12876-023-02924-y","article-title":"CLDN18.2 expression and its impact on prognosis and the immune microenvironment in gastric cancer","volume":"23","author":"Wang","year":"2023","journal-title":"BMC Gastroenterol"},{"issue":"9","key":"10.1016\/j.esmogo.2026.100412_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012683","article-title":"Dynamic modulation of claudin18.2 expression and remodeling of the tumor microenvironment in gastric cancer during chemo-immunotherapy","volume":"13","author":"Lim","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.esmogo.2026.100412_bib56","article-title":"The prognostic role of claudin 18.2 in advanced gastric or gastroesophageal junction adenocarcinoma: a systematic literature review","volume":"9","author":"Fassan","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"issue":"6","key":"10.1016\/j.esmogo.2026.100412_bib57","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1007\/s00428-025-04247-7","article-title":"CLDN18.2 expression in gastroesophageal adenocarcinoma: prevalence, heterogeneity, and prognostic implications in Spanish patients","volume":"487","author":"Martinez-Ciarpaglini","year":"2025","journal-title":"Virchows Arch"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826001123?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826001123?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T09:13:13Z","timestamp":1789031593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826001123"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":57,"alternative-id":["S2949819826001123"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100412","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intra- and intertumoral discordance of Claudin-18.2: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100412","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100412"}}